dihexa hgf c-met agonist Artificial human Met agonists based on macrocycle scaffolds HGF-independent potentiation of EGFR action

Important safety warnings seek urgent medical attention if you experience: Severe or persistent abdominal pain, which may radiate to the back this could indicate pancreatitis , a serious but rare risk associated with GLP-1based therapies as a class [16] [17] Right upper quadrant pain, fever, or jaundice these may suggest gallbladder disease , another class-associated risk Signs of dehydration (dizziness, reduced urine output, extreme thirst) resulting from severe vomiting or diarrhoea, which can affect kidney function Pregnancy and breastfeeding: Use of GLP-1based therapies and related investigational agents is not recommended during pregnancy or breastfeeding

The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint

Yes, but temperature control is the critical constraint

Treatments are particularly beneficial for those experiencing a plateau in their weight loss journey, where further progress seems challenging despite ongoing efforts